Some 45 policymakers from the European Union, member states, academia and the pharmaceutical industry, have for the first time, met to discuss in a neutral forum the future of health care in Europe. Their meeting this month was held under the patronage of the European Parliament, with funding from DGXII of the European Commission, the London School of Economics and the Pharmaceutical Partners for Better Healthcare.
DGXII director general Professor P M Fasella said the key issues addressed were equity and efficiency, and how to balance the role of industry in the health system, and the impact of reforms on industrial performance and viability.
The workshop also underscored the need for a European-wide look at health care reform. The LSE's Professor Brian Abel-Smith pointed out that "countries follow other countries' actions (in health care) without knowing the consequences. It's not just a question of containing costs, other aspects of health care need to be reformed, making services more user-friendly, and encouraging quality and efficiency in every sense."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze